Key Details
Price
$2.08Annual ROE
-142.50%Beta
0.93Events Calendar
Next earnings date:
Mar 7, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 7, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Mar 17, 2021Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its second quarter 2024 financial results and providing a business update on August 21, 2024, at 7:00 am Eastern Time.
Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025.
Chemomab Therapeutics (CMMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug's Direct Interference with Liver Fibroblast Activation— —New Translational Data Further Confirms CM-101's Disease Modifying Activity in Primary Sclerosing Cholangitis— TEL AVIV, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported that it presented two scientific posters supporting the clinical rationale for the company's primary sclerosing cholangitis (PSC) program at EASL 2024, the Annual Congress of the European Association for the Study of the Liver, which is taking place June 5-8, 2024 in Milan, Italy.
Chemomab Therapeutics Ltd., a biotechnology company working on treatments for fibro-inflammatory diseases, will be presenting at the Gordon Research Conference on Chemotactic Cytokines and at EASL 2024, the Annual Congress of the European Association for the Study of the Liver.
The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Adi Mor - Co-Founder and Chief Scientific Officer Matt Frankel - Chief Medical Officer, Vice President of Drug Development Don Marvin - Chief Financial Officer, Executive Vice President & Chief Operating Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab Therapeutics First Quarter 2023 Earnings Call and Corporate Update.
FAQ
- What is the ticker symbol for Chemomab Therapeutics?
- Does Chemomab Therapeutics pay dividends?
- What sector is Chemomab Therapeutics in?
- What industry is Chemomab Therapeutics in?
- What country is Chemomab Therapeutics based in?
- When did Chemomab Therapeutics go public?
- Is Chemomab Therapeutics in the S&P 500?
- Is Chemomab Therapeutics in the NASDAQ 100?
- Is Chemomab Therapeutics in the Dow Jones?
- When was Chemomab Therapeutics's last earnings report?
- When does Chemomab Therapeutics report earnings?
- Should I buy Chemomab Therapeutics stock now?